OKI-219 is an inhibitor of PI3K α H1047R that has brain penetrance and anti-tumor activity in a preclinical intracranial model of metastatic breast cancer

被引：0
|
作者：
Strait, Alexander A.
Taylor, Molly A.
Litwiler, Kevin S.
Zhao, Qian
Mareska, David A.
Boys, Mark L.
Izrayelit, Yevgeniy
Woessner, Richard
Winkler, James D.
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2024-LB174
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LB174
引用
收藏
页数：2
相关论文
共 30 条
  • [1] Discovery and characterization of OKI-219, an orally bioavailable H1047R-mutant-selective inhibitor of PI3Kα
    Taylor, Molly A.
    Zhao, Qian
    Mareska, David
    Hoh, Maria
    Izrayelit, Yevgeniy
    Litwiler, Kevin
    Boys, Mark L.
    Woessner, Rich
    Walker, Duncan
    Diamond, Jennifer
    Winkler, James D.
    [J]. MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [2] LOXO-783: A potent, highly mutant selective and brain-penetrant allosteric PI3Kα H1047R inhibitor in combination with standard of care (SOC) treatments in preclinical PI3Kα H1047R-mutant breast cancer models
    Puca, Loredana
    Dowless, Michele S.
    Perez-Ferreiro, Carmen M.
    Ortiz-Ruiz, Maria Jesus
    Donoho, Gregory P.
    Capen, Andrew
    Huber, Lysiane
    Bogner, Sarah M.
    Fei, Dongling
    Manro, Jason R.
    Yu, Chun Ping
    Xu, Wei Guo
    Wang, Rui
    Chen, Shuang
    Hicks, Mark A.
    Zolfaghari, Parisa
    Faber, Andrew
    Gilmour, Raymond
    Ramstetter, Monica D.
    Chang, Matthew T.
    Lallena, Maria Jose
    Gong, Xuequian
    Hyman, David M.
    Smyth, Lillian M.
    Brandhuber, Barbara J.
    Taylor, Barry S.
    Klippel, Anke
    [J]. CANCER RESEARCH, 2023, 83 (05)
  • [3] OKI-219, a PI3KaH1047R-mutant-selective inhibitor demonstrates efficacy as a single agent and drives combination responses with standard of care therapies in preclinical PI3KaH1047R mutant breast cancer models
    Taylor, Molly A.
    Zhao, Qian
    Mareska, David
    Hoh, Maria
    Izrayelit, Yevgeniy
    Litwiler, Kevin
    Boys, Mark L.
    Woessner, Rich
    Walker, Duncan
    Winkler, James D.
    Diamond, Jennifer
    [J]. CANCER RESEARCH, 2024, 84 (09)
  • [4] Physiological expression of PI3K H1047R mutation reveals its anti-metastatic potential in ErbB2-driven breast cancer
    Simond, Alexandra M.
    Bui, Tung
    Zuo, Dongmei
    Sanguin-Gendreau, Virginie
    Rao, Trisha
    Phillips, Wayne A.
    Cardiff, Robert D.
    Muller, William J.
    [J]. ONCOGENE, 2022, 41 (25) : 3445 - 3451
  • [5] Physiological expression of PI3K H1047R mutation reveals its anti-metastatic potential in ErbB2-driven breast cancer
    Alexandra M. Simond
    Tung Bui
    Dongmei Zuo
    Virginie Sanguin-Gendreau
    Trisha Rao
    Wayne A. Phillips
    Robert D. Cardiff
    William J. Muller
    [J]. Oncogene, 2022, 41 : 3445 - 3451
  • [6] Preclinical characterization of LOX-22783, a highly potent, mutant-selective and brain-penetrant allosteric PI3Kα H1047R inhibitor
    Klippel, Anke
    Wang, Rui
    Puca, Loredana
    Faber, Andrew Lee
    Shen, Weihua
    Bhagwat, Shripad V.
    Karukurichi, Kannan
    Zhang, Feiyu Fred
    Perez, Carmen
    Rama, Ramon
    Ramos, Ana
    Zheng, Yi
    Bonday, Zahid
    Thomas, James
    Brooks, Harold B.
    Kindler, Lisa J.
    Bogner, Sarah M.
    Zolfaghari, Parisa
    Hicks, Mark, II
    Callies, Sophie
    Mattioni, Brian
    LeBrun, Laurie
    Durbin, Jim
    Anderson, Erin
    Mayne, Chris
    Kesicki, Edward
    Kolakowski, Gabrielle
    Andrews, Steven W.
    Brandhuber, Barbara J.
    [J]. MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
  • [7] Discovery of HP567, a highly potent, brain-penetrating, and H1047R-selective PI3K α inhibitor for the treatment of tumors bearing H1047R mutation
    Li, Jing
    Fan, Lei
    Liu, Chengcheng
    Luo, Yao
    Chu, Xiaohui
    Yu, Hua
    Wang, Fei
    Li, Xinghai
    [J]. CANCER RESEARCH, 2024, 84 (07)
  • [8] PI3K inhibitors reduce breast cancer tumor growth and enhance anti-tumor leukocyte activity
    Lavender, Nicole
    Yang, Jinming
    Sai, Jiqing
    Novitskiy, Sergey
    Horton, Linda
    Johnson, Andrew
    Abramson, Vandana
    Mayer, Ingrid
    Meszoely, Ingrid
    Kelley, Mark
    Richmond, Ann
    [J]. CANCER RESEARCH, 2016, 76
  • [9] PI3K/mTOR dual inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A synergistically exert anti-tumor activity in breast cancer
    Chen, Liyan
    Jin, Tiefeng
    Zhu, Kun
    Piao, Yingshi
    Quan, Taihao
    Quan, Chunji
    Lin, Zhenhua
    [J]. ONCOTARGET, 2017, 8 (07) : 11937 - 11949
  • [10] Tolerability and anti-tumor activity of the oral PI3K inhibitor GDC-0941 in combination with paclitaxel, with and without bevacizumab or trastuzumab in patients with locally recurrent or metastatic breast cancer
    Schoffski, Patrick
    Cresta, Sara
    Mayer, Ingrid A.
    Wildiers, Hans
    Rooney, Isabelle
    Apt, Doris
    Gendreau, Steve
    Morrissey, Kari
    Lackner, Mark
    Spoerke, Jill
    Winer, Eric
    [J]. CANCER RESEARCH, 2015, 75
123